No rest for the weary: The Tipline for 7 May 2020

While the Federal Trade Commission’s divided decision to clear Abbvie/Allergan sinks in, Allergan continues to face private antitrust litigation over its efforts to maintain patent exclusivity for dry-eye medication Restasis. A New York federal judge certified a class of Restasis end-purchasers on Tuesday, expressing a high level of confidence in their economic expert’s analysis of the market for dry-eye medication. We also have an update on a record Federal Communications Commission civil penalty resulting from Sinclair’s effort to buy Tribune, and more on House Democrats’ push to ban mergers during the covid-19 pandemic. Our colleagues in London have a public holiday on Friday, so Tipline will be back in your inboxes on Monday.

Unlock unlimited access to all Global Competition Review content